Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

Immunogenicity and protective efficacy of recombinant M2e.Hsp70c (Hsp70(359-610)) fusion protein against influenza virus infection in mice.

Attaran H, Nili H, Tebianian M.

Virol Sin. 2014 Aug;29(4):218-27. doi: 10.1007/s12250-014-3428-8. Epub 2014 Aug 18.

PMID:
25160757
2.

In contrast to conventional inactivated influenza vaccines, 4xM2e.HSP70c fusion protein fully protected mice against lethal dose of H1, H3 and H9 influenza A isolates circulating in Iran.

Ebrahimi SM, Dabaghian M, Tebianian M, Jazi MH.

Virology. 2012 Aug 15;430(1):63-72. doi: 10.1016/j.virol.2012.04.015. Epub 2012 May 16.

3.

A truncated C-terminal fragment of Mycobacterium tuberculosis HSP70 enhances cell-mediated immune response and longevity of the total IgG to influenza A virus M2e protein in mice.

Dabaghian M, Latifi AM, Tebianian M, Dabaghian F, Ebrahimi SM.

Antiviral Res. 2015 Aug;120:23-31. doi: 10.1016/j.antiviral.2015.05.002. Epub 2015 May 16.

PMID:
25989418
4.

Vaccination with recombinant 4 × M2e.HSP70c fusion protein as a universal vaccine candidate enhances both humoral and cell-mediated immune responses and decreases viral shedding against experimental challenge of H9N2 influenza in chickens.

Dabaghian M, Latify AM, Tebianian M, Nili H, Ranjbar AR, Mirjalili A, Mohammadi M, Banihashemi R, Ebrahimi SM.

Vet Microbiol. 2014 Nov 7;174(1-2):116-26. doi: 10.1016/j.vetmic.2014.09.009. Epub 2014 Sep 23.

PMID:
25293397
5.

In vivo electroporation enhances immunogenicity and protection against influenza A virus challenge of an M2e-HSP70c DNA vaccine.

Jazi MH, Dabaghian M, Tebianian M, Gharagozlou MJ, Ebrahimi SM.

Virus Res. 2012 Aug;167(2):219-25. doi: 10.1016/j.virusres.2012.05.002. Epub 2012 May 16.

PMID:
22609252
6.

Complete protection against a H5N2 avian influenza virus by a DNA vaccine expressing a fusion protein of H1N1 HA and M2e.

Park KS, Seo YB, Lee JY, Im SJ, Seo SH, Song MS, Choi YK, Sung YC.

Vaccine. 2011 Jul 26;29(33):5481-7. doi: 10.1016/j.vaccine.2011.05.062. Epub 2011 Jun 12.

PMID:
21664216
7.

Protection against multiple influenza A virus strains induced by candidate recombinant vaccine based on heterologous M2e peptides linked to flagellin.

Stepanova LA, Kotlyarov RY, Kovaleva AA, Potapchuk MV, Korotkov AV, Sergeeva MV, Kasianenko MA, Kuprianov VV, Ravin NV, Tsybalova LM, Skryabin KG, Kiselev OI.

PLoS One. 2015 Mar 23;10(3):e0119520. doi: 10.1371/journal.pone.0119520. eCollection 2015.

8.

Cloning, expression and purification of the influenza A (H9N2) virus M2e antigen and truncated Mycobacterium tuberculosis HSP70 as a fusion protein in Pichia pastoris.

Ebrahimi SM, Tebianian M, Toghyani H, Memarnejadian A, Attaran HR.

Protein Expr Purif. 2010 Mar;70(1):7-12. doi: 10.1016/j.pep.2009.11.001. Epub 2009 Nov 6.

PMID:
19897044
9.

Immunogenicity of live attenuated B. pertussis BPZE1 producing the universal influenza vaccine candidate M2e.

Kammoun H, Roux X, Raze D, Debrie AS, De Filette M, Ysenbaert T, Mielcarek N, Saelens X, Fiers W, Locht C.

PLoS One. 2013;8(3):e59198. doi: 10.1371/journal.pone.0059198. Epub 2013 Mar 19.

10.

Protection against influenza A virus by vaccination with a recombinant fusion protein linking influenza M2e to human serum albumin (HSA).

Mu X, Hu K, Shen M, Kong N, Fu C, Yan W, Wei A.

J Virol Methods. 2016 Feb;228:84-90. doi: 10.1016/j.jviromet.2015.11.014. Epub 2015 Nov 23.

PMID:
26615805
11.

An H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virus.

Zhao G, Sun S, Du L, Xiao W, Ru Z, Kou Z, Guo Y, Yu H, Jiang S, Lone Y, Zheng BJ, Zhou Y.

Virol J. 2010 Jul 12;7:151. doi: 10.1186/1743-422X-7-151.

12.

Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin.

Huleatt JW, Nakaar V, Desai P, Huang Y, Hewitt D, Jacobs A, Tang J, McDonald W, Song L, Evans RK, Umlauf S, Tussey L, Powell TJ.

Vaccine. 2008 Jan 10;26(2):201-14. Epub 2007 Nov 20.

PMID:
18063235
13.

High immunogenicity of plant-produced candidate influenza vaccine based on the M2e peptide fused to flagellin.

Mardanova ES, Kotlyarov RY, Kuprianov VV, Stepanova LA, Tsybalova LM, Lomonossoff GP, Ravin NV.

Bioengineered. 2016;7(1):28-32. doi: 10.1080/21655979.2015.1126017. Epub 2015 Dec 28.

14.

Universal influenza A vaccine: optimization of M2-based constructs.

De Filette M, Min Jou W, Birkett A, Lyons K, Schultz B, Tonkyro A, Resch S, Fiers W.

Virology. 2005 Jun 20;337(1):149-61.

15.

Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant region of hepatitis B core antigen: Broad protective efficacy of particles carrying four copies of M2e.

Tsybalova LM, Stepanova LA, Kuprianov VV, Blokhina EA, Potapchuk MV, Korotkov AV, Gorshkov AN, Kasyanenko MA, Ravin NV, Kiselev OI.

Vaccine. 2015 Jun 26;33(29):3398-406. doi: 10.1016/j.vaccine.2015.04.073. Epub 2015 May 11.

PMID:
25976545
17.

Sublingual immunization with M2-based vaccine induces broad protective immunity against influenza.

Shim BS, Choi YK, Yun CH, Lee EG, Jeon YS, Park SM, Cheon IS, Joo DH, Cho CH, Song MS, Seo SU, Byun YH, Park HJ, Poo H, Seong BL, Kim JO, Nguyen HH, Stadler K, Kim DW, Hong KJ, Czerkinsky C, Song MK.

PLoS One. 2011;6(11):e27953. doi: 10.1371/journal.pone.0027953. Epub 2011 Nov 30.

18.
19.

Immunization with M2e-displaying T7 bacteriophage nanoparticles protects against influenza A virus challenge.

Hashemi H, Pouyanfard S, Bandehpour M, Noroozbabaei Z, Kazemi B, Saelens X, Mokhtari-Azad T.

PLoS One. 2012;7(9):e45765. doi: 10.1371/journal.pone.0045765. Epub 2012 Sep 24.

20.

Prokaryote-expressed M2e protein improves H9N2 influenza vaccine efficacy and protection against lethal influenza A virus in mice.

Kim EH, Lee JH, Pascua PN, Song MS, Baek YH, Kwon HI, Park SJ, Lim GJ, Decano A, Chowdhury MY, Seo SK, Song MK, Kim CJ, Choi YK.

Virol J. 2013 Apr 3;10:104. doi: 10.1186/1743-422X-10-104.

Supplemental Content

Support Center